HDAC-IN-38

HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5)[1].

Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC

Research Areas >> Neurological Disease

Signaling Pathways >> Epigenetics >> HDAC

HDAC8:0.533 μM (IC50)

HDAC6:1.27 μM (IC50)

HDAC3:2.86 μM (IC50)

HDAC1:3.82 μM (IC50)

HDAC5:6.27 μM (IC50)

HDAC2:6.62 μM (IC50)

[1]. Kaur N, et al. Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment. Eur J Med Chem. 2020 Feb 1;187:111915.